

ABSTIMMUNGSVERHALTEN

Novartis AG

Die BVK nimmt ihre Aktionärsrechte in Bezug auf grosskapitalisierte Standardwerte (Blue Chips) innerhalb der Schweiz aktiv wahr. Nachfolgend publizieren wir das Abstimmungsverhalten der BVK an der Generalversammlung 2021.

Angaben zur Generalversammlung Ordentliche Generalversammlung,
02.03.2021

Kennzahlen zur BVK-Beteiligung

Aktienbestand BVK	2'507'000
Anteil BVK am Aktienkapital	0,1%
Marktwert	CHF 203 Mio.
Rendite 1 Jahr	20%

Abstimmungsverhalten BVK

Nr.	Traktandum	Abstimmung
1.	Accept Financial Statements and Statutory Reports	JA
2.	Approve Discharge of Board and Senior Management	JA
3.	Approve Allocation of Income and Dividends of CHF 3.00 per Share	JA
4.	Approve CHF 16.3 Million Reduction in Share Capital via Cancellation of Repurchased Shares	JA
5.	Authorize Repurchase of up to CHF 10 Billion in Issued Share Capital	JA
6.1	Approve Remuneration of Directors in the Amount of CHF 8.6 Million	NEIN
6.2	Approve Maximum Remuneration of Executive Committee in the Amount of CHF 91 Million	NEIN
6.3	Approve Remuneration Report	NEIN
7.1	Reelect Joerg Reinhardt as Director and Board Chairman	JA
7.2	Reelect Nancy Andrews as Director	JA
7.3	Reelect Ton Buechner as Director	JA
7.4	Reelect Patrice Bula as Director	JA
7.5	Reelect Elizabeth Doherty as Director	JA
7.6	Reelect Ann Fudge as Director	JA
7.7	Reelect Bridgette Heller as Director	JA
7.8	Reelect Frans van Houten as Director	JA
7.9	Reelect Simon Moroney as Director	JA
7.10	Reelect Andreas von Planta as Director	JA
7.11	Reelect Charles Sawyers as Director	JA
7.12	Elect Enrico Vanni as Director	JA
7.13	Reelect William Winters as Director	JA
8.1	Reappoint Patrice Bula as Member of the Compensation Committee	NEIN
8.2	Reappoint Bridgette Heller as Member of the Compensation Committee	NEIN

8.3	Reappoint Enrico Vanni as Member of the Compensation Committee	NEIN
8.4	Reappoint William Winters as Member of the Compensation Committee	NEIN
8.5	Appoint Simon Moroney as Member of the Compensation Committee	NEIN
9.	Ratify PricewaterhouseCoopers AG as Auditors	JA
10.	Designate Peter Zahn as Independent Proxy	JA
11.	Amend Articles Re: Board of Directors Tenure	JA
12.	Transact Other Business (Voting)	NEIN